Pasar al contenido principal

Maria Pilar Delgado Martínez

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurovasculares
Vall Hebron Institut de Recerca

Maria Pilar Delgado Martínez

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurovasculares
Vall Hebron Institut de Recerca

Líneas de investigación

L6 Stroke Prevention

Since cerebrovascular diseases and dementia are responsible for a huge economic burden, the early detection of patients at high risk for them, and the implementation of preventive measures as soon as possible, might be of great interest and profit.


The purposes of our research are:


- To promote awareness and knowledge of stroke in the general population and enhance collaboration between primary care services and hospital departments.


- To accurately predict those patients at high-risk for first stroke by the determination of novel risk factors or markers (neuroimaging or biological markers), and therefore to improve stroke risk stratification.


- To incorporate a standardized assessment of cognition in stroke research.


- To determine why interventions may be or not widely applied by means of cost-efficiency studies.


- To study quantitative predictors of preventive treatment compliance.



Future project: “Silent cerebral infarction detection and biomarkers associated with the risk of stroke in hypertensive spanish population”.


Silent cerebral infarctions (SCI) detected with neuroimaging techniques, particularly with brain MRI, are common in aged healthy population and even more frequent in selected patients at risk, such as hypertensive patients.  SCI constitute a preclinical stage of cerebrovascular disease and might precede both stroke and cognitive decline; therefore we think that their identification in hypertensive patients would be an adequate and cost-efficient tool, to avoid further strokes and dementia.


Our current project will include a estimated sample size of 1000 hypertensive patients, without known history of cerebrovascular disease or dementia. Silent Cerebral Infarctions (SCI) will be detected by MRI and the determination of several clinical and biological factors (plasma and genetic biomarkers) will be performed on baseline. The patients will be followed-up for at least 3 years, to assess the presence of incident strokes and/or cognitive impairment.

This study will allow us to determine the prevalence of silent cerebral infarctions in our setting, which is largely unknown.


Also, the identification of SCI will help us to better define the risk stratification in hypertensive patients. Patients at higher risk will be our target population for the development of new preventive strategies based on the results of randomized clinical trials.


Finally, this project will be carried out thanks to the collaboration between Neurovascular Research Laboratory, Primary Care Physicians Services and Nephrology Department of Vall d’Hebron, among others, and therefore, the improvement of the link between Primary Care Systems and the remaining hospitalary services, will favor in the future the preventive treatment and care of the patients.

IP: Maria Pilar Delgado Martínez, Yolanda Riba Llena

Proyectos

Alt risc de Fibril.lació Auricular, Ictus Silent i trastorn COgnitiu: estudi multicéntric, prospectiu i aleatori (PREFA-TE)

IP: -
Colaboradores: Maria Pilar Delgado Martínez
Entidad financiadora: Generalitat de Catalunya - Departament de Salut
Financiación: 27950.35
Referencia: SLT021/21/000027
Duración: 01/04/2022 - 31/12/2024

Malalties neurovasculars

IP: Anna Rosell Novel
Colaboradores: Mercedes Arrue Gonzalo, Joan Montaner Villalonga, Marcel Lamana Vallverdu, Anna Penalba Morenilla, Anna Bonaterra Pastra, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Antonio Palasi Franco, Jesús Pizarro Gonzálvez, Paula Garcia Rodriguez, Miguel García Gabilondo, Nicolas Garcia Rodriguez
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 40000
Referencia: 2021 SGR 00656
Duración: 01/01/2022 - 30/06/2025

RICORS-ICTUS

IP: Anna Rosell Novel
Colaboradores: Marcel Lamana Vallverdu, Anna Penalba Morenilla, Anna Bonaterra Pastra, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Jesús Pizarro Gonzálvez
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 250214.8
Referencia: RD21/0006/0007
Duración: 01/01/2022 - 31/12/2024

PI19. Demencia mixta por enfermedad de Alzheimer y cerebrovascular: un estudio clínico y experimental.

IP: Maria Pilar Delgado Martínez
Colaboradores: -
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 60000
Referencia: INT20/00084
Duración: 01/06/2021 - 31/12/2022

Noticias relacionadas

El programa de formación doctoral de excelencia liderado por la Universidad Autónoma de Barcelona TOUCH MSCA-COFUND, centrado en el ámbito de la salud mental, ha abierto su primera convocatoria, dotada con 13 plazas.

Los grupos de Enfermedades Cardiovasculares y Enfermedades Neurovasculares del VHIR investigarán nuevas estrategias terapéuticas para la insuficiencia cardíaca, nanomedicina en ictus y prevención de la toxicidad cardiovascular en tratamientos de cáncer.

La Comisión de Salud y Medio Ambiente ha impulsado la instalación de plafones situados en los diferentes vestíbulos del hospital en los que se puede ver una silueta humana acompañada de los 17 tipos de enfermedades que causa la contaminación.

Profesionales relacionados

Carlota Pagès Geli

Carlota Pagès Geli

Investigador predoctoral
Leer más
Alejandro Hernández Martínez

Alejandro Hernández Martínez

Cirugía Reconstructiva del Aparato Locomotor
Leer más
Ignacio Iglesias Serrano

Ignacio Iglesias Serrano

Investigador predoctoral
Crecimiento y Desarrollo
Leer más
Sabina Salicrú Riera

Sabina Salicrú Riera

Investigación Biomédica en Ginecología
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.